Insider Buying: Retension Pharmaceuticals (NASDAQ:RTSN) CEO Buys 20,800 Shares of Stock

Retension Pharmaceuticals, Inc. (NASDAQ:RTSN) CEO Eric Keller bought 20,800 shares of Retension Pharmaceuticals stock in a transaction dated Tuesday, October 13th. The shares were acquired at an average price of $12.00 per share, with a total value of $249,600.00. Following the completion of the purchase, the chief executive officer directly owned 423,377 shares in the company, valued at $5,080,524. This trade represents a 5.17% increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.

Retension Pharmaceuticals Stock Up 2.7%

Retension Pharmaceuticals stock traded up $0.31 during mid-day trading on Tuesday, hitting $11.63. 137,519 shares of the company’s stock traded hands, compared to its average volume of 157,559. Retension Pharmaceuticals, Inc. has a fifty-two week low of $9.66 and a fifty-two week high of $12.50.

Retension Pharmaceuticals Company Profile

We are a clinical-stage biopharmaceutical company focused on developing medicines for the treatment of hypertension and other cardiovascular diseases. Our product candidate, RTN-001, is a next-generation, once-daily, oral, small molecule phosphodiesterase-5 (“PDE-5”) inhibitor designed to reduce blood pressure by potentiating nitric oxide signaling, a key mechanism underlying the development and severity of hypertension. While first-generation PDE-5 inhibitors, such as Viagra (sildenafil), were originally studied in cardiovascular indications such as hypertension and angina, we believe they did not have adequate bioavailability and tissue penetration to impact the smooth muscle cells of the central vascular and cardiac tissues and thus failed to achieve clinically meaningful reductions in blood pressure.